855350-51-5

Upstream product

• 944280-23-3 1-[(phenylacetyl)amino]cyclohexanecarboxylic acid phenylmethyl ester 
• 2756-85-6 1-aminocyclohexane carboxylic acid 
• 115951-16-1 1-tert-butoxycarbonylaminocyclohexanecarboxylic acid 
• 17191-43-4 1-{[(benzyloxy)carbonyl]amino}cyclohexanecarboxylic acid 
• 3253-43-8 Spiro<4.5>decan-2,4'-oxazolidine-2,5'-dione 
• 6921-34-2 benzylmagnesium chloride 
• 103-80-0 phenylacetyl chloride 
• 102373-23-9 1-aminocyclohexanecarboxylic acid benzyl ester 

Downstream Products

• 944281-44-1 2-(phenylmethyl)-3-oxa-1-azaspiro[4.5]dec-1-en-4-one 
• 944281-90-7 N-[[1-[[(phenylmethoxy)carbonyl]amino]cyclohexyl]carbonyl]-L-valinol 
• 944281-99-6 N-[[1-[[(Phenylmethoxy)carbonyl]amino]cyclohexyl]carbonyl]-L-valinal 

Relevant academic research and scientific papers

Synthesis of sterically hindered N-acylated amino acids from N-carboxyanhydrides

Sterically hindered N-acyl, gem-disubstituted amino acids are easily prepared via the addition of organometallic reagents to N-carboxyanhydrides (NCA). The process tolerates a wide variety of functional groups and allows the synthesis of amide products not readily accessible by traditional acylation chemistry. The existence of an isocyanate intermediate was established by in situ IR spectroscopy.

α,α-Dialkylglycines obtained by solid phase Ugi reaction performed over isocyanide functionalized resins

The multicomponent Ugi reaction is a straightforward method that can be used for the synthesis of highly hindered C-tetrasubstituted amino acids by reacting an amine, a ketone or aldehyde, a carboxylic acid and an isocyanide. In the present work, the synthesis of several α,α-dialkylglycines (α,α-diethylglycine, Deg; α,α-dipropylglycine, Dpg; 1-amino-1-cyclohexanecarboxylic acid, Ac6c) was achieved by solid phase Ugi reaction using resins functionalized with the isocyanide group. Since no resins with these features were available commercially, the functionalization of an aminomethylated resin started by the use of glycine (Gly), β-alanine (β-Ala) and γ-aminobutyric acid (GABA) as spacers. After spacer N-formylation, followed by dehydration, isocyanide functionalised resins were obtained. The resins were then used in solid phase Ugi reaction, using phenylacetic acid as the acid component, 4-methoxybenzylamine as the amine component and different ketones, to afford the desired N-acylated α,α-dialkylglycines in good overall yields (60-80%), after acidolytic cleavage from the resin, thus proving the feasibility of this approach.

Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same

Cycloalkylcarbonylamino acid derivatives, which are raw material intermediates of a novel cycloalkane carboxamide derivative that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid derivative r

Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same

Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbony

OXAZOLONE DERIVATIVE

Novel raw material compounds are provided that are useful for producing novel cycloalkane carboxamide derivatives having cathepsin K inhibitory action. An oxazolone derivative represented by formula (I): [wherein, R1 represents a substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted phenyl group, substituted or unsubstituted naphthyl group or substituted or unsubstituted heterocyclic group, and ring A represents a saturated cyclic alkylidene group having 6 to 7 carbon atoms].

CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME

Novel cycloalkane carboxamide derivatives having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkane carboxamide derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof: (wherein R1 and R2 represent (substituted) alkyl groups, (substituted) alkenyl groups, (substituted) alkynyl groups, (substituted) aromatic hydrocarbon groups or (substituted) heterocyclic groups, ring A represents an alkylidene group having 5 to 7 carbon atoms, and ring B represents a formyl group or a hydroxymethyl group).